[
  {
    "ts": null,
    "headline": "GLP-1 race evolves as Amgen & weight-loss pills enter the scene",
    "summary": "Amgen (AMGN) is eyeing the obesity drug race, currently dominated by Eli Lilly (LLY) and Novo Nordisk (NVO), with its two late-stage weight-loss drug trials. Citi Research managing director Geoff Meacham joins Market Domination host Josh Lipton to discuss the weight-loss drug market, the advent of pills over injectables, and whether Amgen can stack up to Eli Lilly and Novo Nordisk. To watch more expert insights and analysis on the latest market action, check out more Market Domination.",
    "url": "https://finnhub.io/api/news?id=147905f9e2f8d9968b427debee726b12673a995cdda829ea48380e5da823d035",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758922200,
      "headline": "GLP-1 race evolves as Amgen & weight-loss pills enter the scene",
      "id": 136896926,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Amgen (AMGN) is eyeing the obesity drug race, currently dominated by Eli Lilly (LLY) and Novo Nordisk (NVO), with its two late-stage weight-loss drug trials. Citi Research managing director Geoff Meacham joins Market Domination host Josh Lipton to discuss the weight-loss drug market, the advent of pills over injectables, and whether Amgen can stack up to Eli Lilly and Novo Nordisk. To watch more expert insights and analysis on the latest market action, check out more Market Domination.",
      "url": "https://finnhub.io/api/news?id=147905f9e2f8d9968b427debee726b12673a995cdda829ea48380e5da823d035"
    }
  },
  {
    "ts": null,
    "headline": "EU Approves Lilly's Kisunla for Early Alzheimer's",
    "summary": "Drug shown to slow memory and functional decline in trials",
    "url": "https://finnhub.io/api/news?id=4e58ae7b625ac7688675ca082aa63f190114d5490ec7ac7ca8c2706f193c0077",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758920501,
      "headline": "EU Approves Lilly's Kisunla for Early Alzheimer's",
      "id": 136896927,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Drug shown to slow memory and functional decline in trials",
      "url": "https://finnhub.io/api/news?id=4e58ae7b625ac7688675ca082aa63f190114d5490ec7ac7ca8c2706f193c0077"
    }
  },
  {
    "ts": null,
    "headline": "Heard on the Street Recap: Another Dose of Tariffs",
    "summary": "President Trump unveiled 100% tariffs on pharmaceuticals.  The tariffs, however, only apply to patented or branded drugs and those made by companies that aren't building plants in the U.S. Shares of pharma giants such as Eli Lilly, AstraZeneca, and GSK actually rose slightly.  Luxury furniture seller RH's shares fell 4.2%.",
    "url": "https://finnhub.io/api/news?id=a90311413121e17b29e41f244656c28d6cdfc916f0a113b690f19d3dbb8b7a33",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758919768,
      "headline": "Heard on the Street Recap: Another Dose of Tariffs",
      "id": 136896928,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "President Trump unveiled 100% tariffs on pharmaceuticals.  The tariffs, however, only apply to patented or branded drugs and those made by companies that aren't building plants in the U.S. Shares of pharma giants such as Eli Lilly, AstraZeneca, and GSK actually rose slightly.  Luxury furniture seller RH's shares fell 4.2%.",
      "url": "https://finnhub.io/api/news?id=a90311413121e17b29e41f244656c28d6cdfc916f0a113b690f19d3dbb8b7a33"
    }
  },
  {
    "ts": null,
    "headline": "All bark, no bite: Trump’s latest trade war turns into another TACO salad for Wall Street",
    "summary": "Markets actually improved on the latest surprise round of Trump tariffs.",
    "url": "https://finnhub.io/api/news?id=7cf425f76024ac3ab32825f274a47768aea690dc95adb032973a9f613783d98e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758919246,
      "headline": "All bark, no bite: Trump’s latest trade war turns into another TACO salad for Wall Street",
      "id": 136907470,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Markets actually improved on the latest surprise round of Trump tariffs.",
      "url": "https://finnhub.io/api/news?id=7cf425f76024ac3ab32825f274a47768aea690dc95adb032973a9f613783d98e"
    }
  },
  {
    "ts": null,
    "headline": "Stocks Close Higher After Trump Unveils New Tariffs",
    "summary": "U.S. stocks ended higher Friday after a three-day losing streak, showing investors aren’t concerned about the broad impact of new tariffs on drugs, trucks and furniture.",
    "url": "https://finnhub.io/api/news?id=2e7103a4b46ce12e8363a0817076daf0d2e8a329f7bbfc6c7af0a58bdf05dbea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758918660,
      "headline": "Stocks Close Higher After Trump Unveils New Tariffs",
      "id": 136896929,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "U.S. stocks ended higher Friday after a three-day losing streak, showing investors aren’t concerned about the broad impact of new tariffs on drugs, trucks and furniture.",
      "url": "https://finnhub.io/api/news?id=2e7103a4b46ce12e8363a0817076daf0d2e8a329f7bbfc6c7af0a58bdf05dbea"
    }
  },
  {
    "ts": null,
    "headline": "These Stocks Moved the Most Today: Eli Lilly, Electronic Arts, Intel, GlobalFoundries, Boeing, AppLovin, Costco, and More",
    "summary": "Eli Lilly rises after President Donald Trump announces a 100% tariff on drug products from companies not building manufacturing plants in the U.S.",
    "url": "https://finnhub.io/api/news?id=a681de560608ef59dc0eff72a34bda25721399333a7fc2d8648db11618f3b10b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758917700,
      "headline": "These Stocks Moved the Most Today: Eli Lilly, Electronic Arts, Intel, GlobalFoundries, Boeing, AppLovin, Costco, and More",
      "id": 136896930,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly rises after President Donald Trump announces a 100% tariff on drug products from companies not building manufacturing plants in the U.S.",
      "url": "https://finnhub.io/api/news?id=a681de560608ef59dc0eff72a34bda25721399333a7fc2d8648db11618f3b10b"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Gain Late Afternoon",
    "summary": "Health care stocks rose late Friday afternoon, with the NYSE Health Care Index and the Health Care S",
    "url": "https://finnhub.io/api/news?id=3c38ac59c14311610bb78196a92b4b82d5036639f369412b75d298040dc6b64d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758916063,
      "headline": "Sector Update: Health Care Stocks Gain Late Afternoon",
      "id": 136896931,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Health care stocks rose late Friday afternoon, with the NYSE Health Care Index and the Health Care S",
      "url": "https://finnhub.io/api/news?id=3c38ac59c14311610bb78196a92b4b82d5036639f369412b75d298040dc6b64d"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Rise Friday Afternoon",
    "summary": "Health care stocks advanced Friday afternoon, with the NYSE Health Care Index up 0.7% and the Health",
    "url": "https://finnhub.io/api/news?id=70a4270a43b42c54c14373e38cbca4be6a989ee3c8b43460324e1eba5c3f8479",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758908710,
      "headline": "Sector Update: Health Care Stocks Rise Friday Afternoon",
      "id": 136896932,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Health care stocks advanced Friday afternoon, with the NYSE Health Care Index up 0.7% and the Health",
      "url": "https://finnhub.io/api/news?id=70a4270a43b42c54c14373e38cbca4be6a989ee3c8b43460324e1eba5c3f8479"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly, Pfizer, Amgen Stocks Rise After Trump’s 100% Pharma Tariff Threat. Here’s Why.",
    "summary": "Eli Lilly, Pfizer, Amgen Stocks Rise After Trump’s 100% Pharma Tariff Threat. Here’s Why.",
    "url": "https://finnhub.io/api/news?id=419b097963dfa4a43b4a84cafebb9ef46b0d55a5dafa5472eb05116de58124f3",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758905460,
      "headline": "Eli Lilly, Pfizer, Amgen Stocks Rise After Trump’s 100% Pharma Tariff Threat. Here’s Why.",
      "id": 136921039,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly, Pfizer, Amgen Stocks Rise After Trump’s 100% Pharma Tariff Threat. Here’s Why.",
      "url": "https://finnhub.io/api/news?id=419b097963dfa4a43b4a84cafebb9ef46b0d55a5dafa5472eb05116de58124f3"
    }
  },
  {
    "ts": null,
    "headline": "Hims & Hers: Navigating GLP Controversy With Aplomb, But Risks Warrant Hold Rating",
    "summary": "Get the latest analysis on Hims & Hers Health, Inc. stock with valuation insights, business risks, and forecasts. Click here to find out why HIMS is a Hold.",
    "url": "https://finnhub.io/api/news?id=676d28e363cdaa4c76a46a539c110957b426f3890c7978c39711a16c7d8a61b6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758901984,
      "headline": "Hims & Hers: Navigating GLP Controversy With Aplomb, But Risks Warrant Hold Rating",
      "id": 136894993,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1343278493/image_1343278493.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Get the latest analysis on Hims & Hers Health, Inc. stock with valuation insights, business risks, and forecasts. Click here to find out why HIMS is a Hold.",
      "url": "https://finnhub.io/api/news?id=676d28e363cdaa4c76a46a539c110957b426f3890c7978c39711a16c7d8a61b6"
    }
  },
  {
    "ts": null,
    "headline": "Has AbbVie Successfully Navigated Top-line Growth Post Humira LOE?",
    "summary": "ABBV eyes a 2025 rebound as Skyrizi and Rinvoq drive growth beyond Humira, with oncology and neuroscience adding momentum.",
    "url": "https://finnhub.io/api/news?id=f94823b0b710280a05310f850e35629c0191f2798fbdc1ec587b9d079aefbf90",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758901500,
      "headline": "Has AbbVie Successfully Navigated Top-line Growth Post Humira LOE?",
      "id": 136896933,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "ABBV eyes a 2025 rebound as Skyrizi and Rinvoq drive growth beyond Humira, with oncology and neuroscience adding momentum.",
      "url": "https://finnhub.io/api/news?id=f94823b0b710280a05310f850e35629c0191f2798fbdc1ec587b9d079aefbf90"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly terminates trial of Zepbound and muscle-sparing combo",
    "summary": "Though the trial for patients with obesity and type 2 diabetes will come to an end, an obesity-only trial will continue.",
    "url": "https://finnhub.io/api/news?id=5349aca27ba7c9f0e602ee79bd3682eed1a8a0153ec89d829875fc3b5cf79ca9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758899927,
      "headline": "Eli Lilly terminates trial of Zepbound and muscle-sparing combo",
      "id": 136892597,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Though the trial for patients with obesity and type 2 diabetes will come to an end, an obesity-only trial will continue.",
      "url": "https://finnhub.io/api/news?id=5349aca27ba7c9f0e602ee79bd3682eed1a8a0153ec89d829875fc3b5cf79ca9"
    }
  },
  {
    "ts": null,
    "headline": "Wells Fargo Reiterates Buy Rating on Eli Lilly and Company Stock, Maintains PT at $1,000",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the 10 Best AI Stocks to Buy According to Goldman Sachs. On September 18, Wells Fargo reiterated a Buy rating on Eli Lilly and Company (NYSE:LLY) stock, maintaining the price target at $1,100. Mohit Bansal from Wells Fargo reaffirmed his rating on LLY following the company’s announcement […]",
    "url": "https://finnhub.io/api/news?id=869b59cb14c1dd7a425dab2ac3e19fb7063a0e4181831e347d81245f741a0b5a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758898786,
      "headline": "Wells Fargo Reiterates Buy Rating on Eli Lilly and Company Stock, Maintains PT at $1,000",
      "id": 136892598,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the 10 Best AI Stocks to Buy According to Goldman Sachs. On September 18, Wells Fargo reiterated a Buy rating on Eli Lilly and Company (NYSE:LLY) stock, maintaining the price target at $1,100. Mohit Bansal from Wells Fargo reaffirmed his rating on LLY following the company’s announcement […]",
      "url": "https://finnhub.io/api/news?id=869b59cb14c1dd7a425dab2ac3e19fb7063a0e4181831e347d81245f741a0b5a"
    }
  },
  {
    "ts": null,
    "headline": "A New Prescription For Pain: Understanding Trump's 100% Pharma Tariff",
    "summary": "Discover how Trumpâs 100% drug tariff impacts NVO, SNY, and AZN stocks. Click for which pharma giants face the most riskâand the upside for savvy investors.",
    "url": "https://finnhub.io/api/news?id=b99ed538cfce6e754748d0d9491a18f0981b43458fb4979d2754deaa33e6d894",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758897431,
      "headline": "A New Prescription For Pain: Understanding Trump's 100% Pharma Tariff",
      "id": 136894575,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2231870275/image_2231870275.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Discover how Trumpâs 100% drug tariff impacts NVO, SNY, and AZN stocks. Click for which pharma giants face the most riskâand the upside for savvy investors.",
      "url": "https://finnhub.io/api/news?id=b99ed538cfce6e754748d0d9491a18f0981b43458fb4979d2754deaa33e6d894"
    }
  },
  {
    "ts": null,
    "headline": "LLY Gets EU Approval for Alzheimer's Drug & FDA Nod to Cancer Therapy",
    "summary": "Eli Lilly secures EU approval for Alzheimer's drug Kisunla and gains FDA nod to breast cancer therapy Inluriyo.",
    "url": "https://finnhub.io/api/news?id=b5a7101300726ccd7ef7827daf509c85adfa24e35ee74d25e616933967c41751",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758897120,
      "headline": "LLY Gets EU Approval for Alzheimer's Drug & FDA Nod to Cancer Therapy",
      "id": 136896934,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly secures EU approval for Alzheimer's drug Kisunla and gains FDA nod to breast cancer therapy Inluriyo.",
      "url": "https://finnhub.io/api/news?id=b5a7101300726ccd7ef7827daf509c85adfa24e35ee74d25e616933967c41751"
    }
  },
  {
    "ts": null,
    "headline": "The Stock Market Is Up, but the Dollar Is Down. What It Means for You.",
    "summary": "Morgan Stanley notes that the dollar’s drop this year is the biggest decline since 1973 and says the greenback “could lose another 10% by the end of 2026.”",
    "url": "https://finnhub.io/api/news?id=41e7441b8ee7f96bfcfbc893be76e672ca103911a3c9b2cf9e1b727e6afbfa82",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758895740,
      "headline": "The Stock Market Is Up, but the Dollar Is Down. What It Means for You.",
      "id": 136897636,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Morgan Stanley notes that the dollar’s drop this year is the biggest decline since 1973 and says the greenback “could lose another 10% by the end of 2026.”",
      "url": "https://finnhub.io/api/news?id=41e7441b8ee7f96bfcfbc893be76e672ca103911a3c9b2cf9e1b727e6afbfa82"
    }
  },
  {
    "ts": null,
    "headline": "Trump's new tariffs on pharma, furniture, & trucks: What to know",
    "summary": "President Trump announced sweeping new tariffs on pharmaceuticals, heavy trucks, and furniture imports. The duty on pharmaceuticals sits at 100% for patented drugs unless the producer is building a manufacturing plant in the US. White House columnist for The Hill, Niall Stanage, and Yahoo Finance senior reporter Brooke DiPalma outline the details of the tariff policy and examine the respective market reactions. To watch more expert insights and analysis on the latest market action, check out more Morning Brief.",
    "url": "https://finnhub.io/api/news?id=d7991ae95fc41cdc2d33538ff9b6e84b21dd938423a6bbf5b5aea179b58efa25",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758895101,
      "headline": "Trump's new tariffs on pharma, furniture, & trucks: What to know",
      "id": 136892599,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "President Trump announced sweeping new tariffs on pharmaceuticals, heavy trucks, and furniture imports. The duty on pharmaceuticals sits at 100% for patented drugs unless the producer is building a manufacturing plant in the US. White House columnist for The Hill, Niall Stanage, and Yahoo Finance senior reporter Brooke DiPalma outline the details of the tariff policy and examine the respective market reactions. To watch more expert insights and analysis on the latest market action, check out more Morning Brief.",
      "url": "https://finnhub.io/api/news?id=d7991ae95fc41cdc2d33538ff9b6e84b21dd938423a6bbf5b5aea179b58efa25"
    }
  },
  {
    "ts": null,
    "headline": "Stocks Rise After Trump Unveils New Tariffs",
    "summary": "President Trump unveiled new tariffs on drugs, trucks and furniture.  U.S. stocks rose, putting them on track to break a three-day losing streak.  Trump said the 100% levy would apply only to patented or branded drugs, and to those sold by companies that aren’t building plants in America.",
    "url": "https://finnhub.io/api/news?id=856bff1ba18617b6a487cbab7a346d6f0b0f883984bcb3dc4937968a7dd39772",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758895020,
      "headline": "Stocks Rise After Trump Unveils New Tariffs",
      "id": 136892600,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "President Trump unveiled new tariffs on drugs, trucks and furniture.  U.S. stocks rose, putting them on track to break a three-day losing streak.  Trump said the 100% levy would apply only to patented or branded drugs, and to those sold by companies that aren’t building plants in America.",
      "url": "https://finnhub.io/api/news?id=856bff1ba18617b6a487cbab7a346d6f0b0f883984bcb3dc4937968a7dd39772"
    }
  },
  {
    "ts": null,
    "headline": "These Stocks Are Moving the Most Today: Eli Lilly, Intel, Paccar, GlobalFoundries, Boeing, Concentrix, Costco, and More",
    "summary": "Pharmaceutical stocks such as Eli Lilly rise after President Donald Trump announces a 100% tariff on drug products from companies not building manufacturing plants in the U.S.",
    "url": "https://finnhub.io/api/news?id=33afab771edecbeaf6ba4ce9219551115f69ab73f2ea05204a8b53607139e13d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758894900,
      "headline": "These Stocks Are Moving the Most Today: Eli Lilly, Intel, Paccar, GlobalFoundries, Boeing, Concentrix, Costco, and More",
      "id": 136892601,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Pharmaceutical stocks such as Eli Lilly rise after President Donald Trump announces a 100% tariff on drug products from companies not building manufacturing plants in the U.S.",
      "url": "https://finnhub.io/api/news?id=33afab771edecbeaf6ba4ce9219551115f69ab73f2ea05204a8b53607139e13d"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly, Merck, Pfizer Stocks Rise After Trump Unveils Pharma Tariffs",
    "summary": "Big U.S. and European drugmakers largely brushed off President Trump's new pharmaceutical tariffs, though some Asian companies suffered losses.  Trump on Thursday announced a 100% tariff on branded or patented drugs from companies that aren't building plants in America.  Generic drugs are exempt from the levy.",
    "url": "https://finnhub.io/api/news?id=4d27bfd0b6a8bdded47d43f3896fadc309e37c9e690cc4233457e9f6456324dc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758894528,
      "headline": "Eli Lilly, Merck, Pfizer Stocks Rise After Trump Unveils Pharma Tariffs",
      "id": 136892602,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Big U.S. and European drugmakers largely brushed off President Trump's new pharmaceutical tariffs, though some Asian companies suffered losses.  Trump on Thursday announced a 100% tariff on branded or patented drugs from companies that aren't building plants in America.  Generic drugs are exempt from the levy.",
      "url": "https://finnhub.io/api/news?id=4d27bfd0b6a8bdded47d43f3896fadc309e37c9e690cc4233457e9f6456324dc"
    }
  },
  {
    "ts": null,
    "headline": "Factbox-Global drugmakers rush to boost US presence as tariff threat looms",
    "summary": "However, with many countries still engaged in trade talks with the U.S., businesses worldwide are hedging their decisions pending further clarity on final tariff rates.  The London-based drugmaker plans to invest $30 billion in U.S. research and development and supply chain infrastructure over five years.  The U.S. drugmaker said in September it will invest $5 billion to build a manufacturing facility in Virginia.",
    "url": "https://finnhub.io/api/news?id=c027880675a138f62e3f19f8862ee3709ef4db58cd5580b3fcecd80aca114319",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758894523,
      "headline": "Factbox-Global drugmakers rush to boost US presence as tariff threat looms",
      "id": 136892603,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "However, with many countries still engaged in trade talks with the U.S., businesses worldwide are hedging their decisions pending further clarity on final tariff rates.  The London-based drugmaker plans to invest $30 billion in U.S. research and development and supply chain infrastructure over five years.  The U.S. drugmaker said in September it will invest $5 billion to build a manufacturing facility in Virginia.",
      "url": "https://finnhub.io/api/news?id=c027880675a138f62e3f19f8862ee3709ef4db58cd5580b3fcecd80aca114319"
    }
  },
  {
    "ts": null,
    "headline": "Trump Slams 100% Tariff on Imported Drugs: Pharma ETFs Take a Hit",
    "summary": "Trump's 100% tariff on imported drugs jolts markets, slamming pharma giants and dragging ETFs like XPH, FTXH, IHE, and PPH lower.",
    "url": "https://finnhub.io/api/news?id=7279f6519b2a590768586751669050dbc70f83812e87aaceb7775a35761c18d5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758893040,
      "headline": "Trump Slams 100% Tariff on Imported Drugs: Pharma ETFs Take a Hit",
      "id": 136892605,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Trump's 100% tariff on imported drugs jolts markets, slamming pharma giants and dragging ETFs like XPH, FTXH, IHE, and PPH lower.",
      "url": "https://finnhub.io/api/news?id=7279f6519b2a590768586751669050dbc70f83812e87aaceb7775a35761c18d5"
    }
  },
  {
    "ts": null,
    "headline": "Big pharma stocks rise as Street reacts to latest presidential tariff plan",
    "summary": "Shares of some big drugmakers jumped ahead of broader indexes Friday as Wall Street started sorting out President Donald Trump’s latest tariff announcement.  The president said late Thursday that he would place 100% import taxes on pharmaceuticals starting Oct. 1, but those tariffs would not apply to companies building U.S. manufacturing plants.  Several big drugmakers like Merck & Co. Inc., Eli Lilly and Co. and Johnson & Johnson have announced U.S. expansion plans.",
    "url": "https://finnhub.io/api/news?id=4b37a7be94a8687633bc24664a4565f06a7e6f2105839c6b4d6ce3ced85e7422",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758892447,
      "headline": "Big pharma stocks rise as Street reacts to latest presidential tariff plan",
      "id": 136892606,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Shares of some big drugmakers jumped ahead of broader indexes Friday as Wall Street started sorting out President Donald Trump’s latest tariff announcement.  The president said late Thursday that he would place 100% import taxes on pharmaceuticals starting Oct. 1, but those tariffs would not apply to companies building U.S. manufacturing plants.  Several big drugmakers like Merck & Co. Inc., Eli Lilly and Co. and Johnson & Johnson have announced U.S. expansion plans.",
      "url": "https://finnhub.io/api/news?id=4b37a7be94a8687633bc24664a4565f06a7e6f2105839c6b4d6ce3ced85e7422"
    }
  },
  {
    "ts": null,
    "headline": "FDA Approves Eli Lilly's Drug For Advanced Breast Cancer",
    "summary": "On Thursday, the U.S. Food and Drug Administration (FDA) approved Eli Lilly and Co.’s (NYSE: LLY) Inluriyo (imlunestrant) for adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2–), ESR1-mutated advanced or metastatic breast cancer (MBC) whose disease progressed after at least one line of endocrine therapy (ET). The FDA approval is based on the results of the EMBER-3 trial in the patient population harboring ESR1-mutated MBC (n=256). In the Phase",
    "url": "https://finnhub.io/api/news?id=915e775e7b9ef441265cce9004ece6ea15920cba2f44d2a3b191af08f73e7af7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758892358,
      "headline": "FDA Approves Eli Lilly's Drug For Advanced Breast Cancer",
      "id": 136892607,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "On Thursday, the U.S. Food and Drug Administration (FDA) approved Eli Lilly and Co.’s (NYSE: LLY) Inluriyo (imlunestrant) for adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2–), ESR1-mutated advanced or metastatic breast cancer (MBC) whose disease progressed after at least one line of endocrine therapy (ET). The FDA approval is based on the results of the EMBER-3 trial in the patient population harboring ESR1-mutated MBC (n=256). In the Phase",
      "url": "https://finnhub.io/api/news?id=915e775e7b9ef441265cce9004ece6ea15920cba2f44d2a3b191af08f73e7af7"
    }
  },
  {
    "ts": null,
    "headline": "Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday Amid New Tariffs",
    "summary": "The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.2% and the actively trad",
    "url": "https://finnhub.io/api/news?id=df6212a16c2b0422d0de18f95d0f6aac89baa0ed6f6281f7ca2ced35bc5afda0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758891935,
      "headline": "Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday Amid New Tariffs",
      "id": 136892553,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.2% and the actively trad",
      "url": "https://finnhub.io/api/news?id=df6212a16c2b0422d0de18f95d0f6aac89baa0ed6f6281f7ca2ced35bc5afda0"
    }
  },
  {
    "ts": null,
    "headline": "Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock",
    "summary": "Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.",
    "url": "https://finnhub.io/api/news?id=91f1d79bfed3fc6a501432c1c45d18f9ca955d70bc8bf49f31972a27cfadc07d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758891605,
      "headline": "Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock",
      "id": 136892609,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.",
      "url": "https://finnhub.io/api/news?id=91f1d79bfed3fc6a501432c1c45d18f9ca955d70bc8bf49f31972a27cfadc07d"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer Asserts You’ve “Gotta Stick With” Eli Lilly and Company (LLY)",
    "summary": "We recently published 14 Stocks Jim Cramer Discussed Including His 2 Top Quantum Computing Stocks. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently discussed. Even though Eli Lilly and Company (NYSE:LLY)’s shares have lost 6.9% year-to-date, Cramer continues to be a believer in the stock. He believes that the firm […]",
    "url": "https://finnhub.io/api/news?id=2b2ccfb47b876a2345eb688a7f62ef2360cc03422afae67c964086762a7e7b2c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758891331,
      "headline": "Jim Cramer Asserts You’ve “Gotta Stick With” Eli Lilly and Company (LLY)",
      "id": 136892610,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published 14 Stocks Jim Cramer Discussed Including His 2 Top Quantum Computing Stocks. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently discussed. Even though Eli Lilly and Company (NYSE:LLY)’s shares have lost 6.9% year-to-date, Cramer continues to be a believer in the stock. He believes that the firm […]",
      "url": "https://finnhub.io/api/news?id=2b2ccfb47b876a2345eb688a7f62ef2360cc03422afae67c964086762a7e7b2c"
    }
  },
  {
    "ts": null,
    "headline": "Lilly opens newest Gateway Labs site in San Diego to boost local biotechnology ecosystem",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced the official opening of its newest Lilly Gateway Labs (LGL) site in San Diego, California, expanding its network of shared innovation hubs designed to support early-stage biotechnology companies by providing lab space and opportunities to collaborate with Lilly scientists.",
    "url": "https://finnhub.io/api/news?id=6f38b32cbd40d3822003b2e1c27b86630ef55a288e2acd58eaeeb58e49c8ec3a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758889800,
      "headline": "Lilly opens newest Gateway Labs site in San Diego to boost local biotechnology ecosystem",
      "id": 136892612,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced the official opening of its newest Lilly Gateway Labs (LGL) site in San Diego, California, expanding its network of shared innovation hubs designed to support early-stage biotechnology companies by providing lab space and opportunities to collaborate with Lilly scientists.",
      "url": "https://finnhub.io/api/news?id=6f38b32cbd40d3822003b2e1c27b86630ef55a288e2acd58eaeeb58e49c8ec3a"
    }
  },
  {
    "ts": null,
    "headline": "Alexandria Real Estate Equities, Inc. Strategically Partners With Lilly on Newest Lilly Gateway Labs at the One Alexandria Square Megacampus in San Diego's Torrey Pines to Accelerate the Development of Life-Changing Medicines",
    "summary": "Alexandria Real Estate Equities, Inc. (NYSE: ARE), the first, preeminent, longest-tenured and pioneering owner, operator, and developer of collaborative Megacampus™ ecosystems in AAA life science innovation cluster locations, today announced the opening of Lilly Gateway Labs San Diego, powered by Alexandria, on the One Alexandria Square Megacampus in Torrey Pines. First launched by Eli Lilly and Company in 2019 in the San Francisco Bay Area, Lilly Gateway Labs is a shared innovation hub designed",
    "url": "https://finnhub.io/api/news?id=e39d9911f0193d8cbebe2f05f8857239d0d161a7c55dad9b21019b327399f750",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758889800,
      "headline": "Alexandria Real Estate Equities, Inc. Strategically Partners With Lilly on Newest Lilly Gateway Labs at the One Alexandria Square Megacampus in San Diego's Torrey Pines to Accelerate the Development of Life-Changing Medicines",
      "id": 136892611,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Alexandria Real Estate Equities, Inc. (NYSE: ARE), the first, preeminent, longest-tenured and pioneering owner, operator, and developer of collaborative Megacampus™ ecosystems in AAA life science innovation cluster locations, today announced the opening of Lilly Gateway Labs San Diego, powered by Alexandria, on the One Alexandria Square Megacampus in Torrey Pines. First launched by Eli Lilly and Company in 2019 in the San Francisco Bay Area, Lilly Gateway Labs is a shared innovation hub designed",
      "url": "https://finnhub.io/api/news?id=e39d9911f0193d8cbebe2f05f8857239d0d161a7c55dad9b21019b327399f750"
    }
  },
  {
    "ts": null,
    "headline": "Intel, Wayfair, Eli Lilly, Oracle: Trending tickers",
    "summary": "Stocks are moving this morning on President Trump's new tariffs and trade announcements - even as governments and companies seek more clarity. Intel (INTC) is rallying on the news of new rules to favor US-manufactured chips; Investors sell Wayfair (W); truck maker Paccar (PCAR) soars, while European rivals are in the red; Eli Lilly (LLY) ticks up ahead of a new 100% tariff on some imported drugs slated for October 1st. And watch Boeing (BA) and Oracle (ORCL) as they find themselves increasingly at the center of US diplomacy. For more live coverage of markets watch the full episode of Market Sunrise and head to Yahoo Finance.",
    "url": "https://finnhub.io/api/news?id=740e9d26547e21b805ad23cb67480842704a10b779f5a2b14098fee759417bc6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758888883,
      "headline": "Intel, Wayfair, Eli Lilly, Oracle: Trending tickers",
      "id": 136892613,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Stocks are moving this morning on President Trump's new tariffs and trade announcements - even as governments and companies seek more clarity. Intel (INTC) is rallying on the news of new rules to favor US-manufactured chips; Investors sell Wayfair (W); truck maker Paccar (PCAR) soars, while European rivals are in the red; Eli Lilly (LLY) ticks up ahead of a new 100% tariff on some imported drugs slated for October 1st. And watch Boeing (BA) and Oracle (ORCL) as they find themselves increasingly at the center of US diplomacy. For more live coverage of markets watch the full episode of Market Sunrise and head to Yahoo Finance.",
      "url": "https://finnhub.io/api/news?id=740e9d26547e21b805ad23cb67480842704a10b779f5a2b14098fee759417bc6"
    }
  },
  {
    "ts": null,
    "headline": "President Trump's 100% Tariff Threat: What It Means For Your Pharma Portfolio",
    "summary": "Explore how Trump's MFN pricing and 100% drug import tariffs impact pharma stocks.",
    "url": "https://finnhub.io/api/news?id=f87454e5d95e6da200bbd80a0968fd7d3fa1631bf2ee86d435f94ffa5e918741",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758885865,
      "headline": "President Trump's 100% Tariff Threat: What It Means For Your Pharma Portfolio",
      "id": 136892883,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1645808639/image_1645808639.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Explore how Trump's MFN pricing and 100% drug import tariffs impact pharma stocks.",
      "url": "https://finnhub.io/api/news?id=f87454e5d95e6da200bbd80a0968fd7d3fa1631bf2ee86d435f94ffa5e918741"
    }
  },
  {
    "ts": null,
    "headline": "FDA approves Lilly’s Inluriyo to treat advanced breast cancer",
    "summary": "The approval was based on results from the Phase III EMBER-3 trial in 256 patients.",
    "url": "https://finnhub.io/api/news?id=d69ec68dff630d95ca55da29df06ae9d53b066a60916ad22e0625c45c4f03dc1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758877747,
      "headline": "FDA approves Lilly’s Inluriyo to treat advanced breast cancer",
      "id": 136892614,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The approval was based on results from the Phase III EMBER-3 trial in 256 patients.",
      "url": "https://finnhub.io/api/news?id=d69ec68dff630d95ca55da29df06ae9d53b066a60916ad22e0625c45c4f03dc1"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's GLP-1 Pill Just Beat Out Novo Nordisk's in a Test. Here's 1 Thing Investors Need to Know.",
    "summary": "Recent data from a head-to-head trial was positive for Eli Lilly, but it's not the whole story.",
    "url": "https://finnhub.io/api/news?id=3c3fd3cb70f821b005aeb9a19ab491fbd1e96013dbf7e1a0ad74083645fea302",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758874860,
      "headline": "Eli Lilly's GLP-1 Pill Just Beat Out Novo Nordisk's in a Test. Here's 1 Thing Investors Need to Know.",
      "id": 136892615,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Recent data from a head-to-head trial was positive for Eli Lilly, but it's not the whole story.",
      "url": "https://finnhub.io/api/news?id=3c3fd3cb70f821b005aeb9a19ab491fbd1e96013dbf7e1a0ad74083645fea302"
    }
  },
  {
    "ts": null,
    "headline": "Trump Plans New Tariff Push With 100% Rate on Patented Drugs",
    "summary": "“Starting October 1st, 2025, we will be imposing a 100% Tariff on any branded or patented Pharmaceutical Product, unless a Company IS BUILDING their Pharmaceutical Manufacturing Plant in America,” Trump posted on social media Thursday, without offering specifics on which producers will be impacted.  “There will, therefore, be no Tariff on these Pharmaceutical Products if construction has started.”",
    "url": "https://finnhub.io/api/news?id=405bb7558df757d18271ae19363d916f178b5c7324db98af9d47ec112ffd5d4e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758871035,
      "headline": "Trump Plans New Tariff Push With 100% Rate on Patented Drugs",
      "id": 136890601,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "“Starting October 1st, 2025, we will be imposing a 100% Tariff on any branded or patented Pharmaceutical Product, unless a Company IS BUILDING their Pharmaceutical Manufacturing Plant in America,” Trump posted on social media Thursday, without offering specifics on which producers will be impacted.  “There will, therefore, be no Tariff on these Pharmaceutical Products if construction has started.”",
      "url": "https://finnhub.io/api/news?id=405bb7558df757d18271ae19363d916f178b5c7324db98af9d47ec112ffd5d4e"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly obtains marketing authorization for Kisunla in EU",
    "summary": "Eli Lilly announces that the European Commission has authorized the marketing of Kisunla for the treatment of early-stage Alzheimer's disease in adults with mild cognitive impairment or mild dementia...",
    "url": "https://finnhub.io/api/news?id=3a17834db183b3c6b40e91fd0cc4506e7d5fbdee3d17c49daa8720ede659ae08",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758863426,
      "headline": "Eli Lilly obtains marketing authorization for Kisunla in EU",
      "id": 136891167,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly announces that the European Commission has authorized the marketing of Kisunla for the treatment of early-stage Alzheimer's disease in adults with mild cognitive impairment or mild dementia...",
      "url": "https://finnhub.io/api/news?id=3a17834db183b3c6b40e91fd0cc4506e7d5fbdee3d17c49daa8720ede659ae08"
    }
  }
]